Estrella Immunopharma names Hong Zhang as chairperson

Estrella Immunopharma announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the company dosed the first patient in its Phase I/II clinical trial for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. Zhang’s appointment increases the size of Estrella’s Board from five to six directors. Cheng Liu, Estrella’s CEO and previous Chairman, will continue to serve as a director on the Board.